ArticleBMC gastroenterology2025
IgG4-related cholangitis - distinguishing from other benign biliary strictures: clinical features, imaging, and response to treatment: a retrospective study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgG4-related cholangitis (IRC) is a rare systemic fibroinflammatory disorder that can affect multiple secretory organs, posing diagnostic challenges. It mimics both benign biliary strictures (BBS) and malignant biliary strictures (MBS). A hallmark feature of IRC is its dramatic response to systemic corticosteroids. Misdiagnosis may lead to incorrect treatment or unwarranted surgical procedures. This study aimed to compare the baseline characteristics, laboratory test results, imaging findings, and treatment responses between IRC and other BBS groups.
methodsWe reviewed all patients with a definitive diagnosis of BBS between January 2013 and January 2023. Data on serum bilirubin, serum IgG4 level, stent type, and response to treatment were collected. The baseline characteristics, biliary stricture treatment, and stent indwelling time were compared between the IRC and other BBS groups.
resultsA total of 158 patients with BBS were included (IRC, n = 19; other BBS, n = 139). The mean age was 59 years, and 62% were male. No significant difference in comorbidities or initial laboratory results was observed between the two groups. The IRC group had significantly higher rates of jaundice (73.7% vs. 29.7%, p < 0.001) and coexisting autoimmune pancreatitis (52.6% vs. 0%, p < 0.001). Patients with IRC had significantly higher serum IgG4 levels (5.384 g/L vs. 0.838 g/L, p < 0.001) and longer stricture lengths (23 mm vs. 7 mm, p < 0.001). Patients with IRC achieved complete responses to medication without requiring prolonged endoscopic stenting or surgery. Key diagnostic factors for IRC included being male (odds ratio [OR] 3.71, 95% confidence interval [CI] 1.03-13.32, p = 0.045), uniform circumferential bile duct thickening (OR 5.00, 95% CI 1.82-13.69, p = 0.002), long stricture length (> 15 mm) (OR 5.72, 95% CI 2.02-16.19, p = 0.001), The multivariate analysis demonstrated tissue lymphoplasmacytic infiltration (OR 88.38, 95% CI 7.98-978.53, P < 0.001) and Cholangiography type I (OR 22.47, 95% CI 2.63-192.26, p = 0.004).
conclusionsIRC can be distinguished from other BBS through specific clinical and imaging features. Elevated serum IgG4 levels and tissue staining for IgG4-positive cells aid in accurate diagnosis. Recognising IRC, even in low-prevalence areas, guides appropriate treatment and avoids unnecessary surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.